SUBSCRIBE
SUBSCRIBE
News   Drug Development

MediGene, Inc. Drug Extends Pancreatic Cancer Survival

September 16, 2008 | 
1 min read

LONDON, Sept 16 (Reuters) - Patients with inoperable pancreatic cancer live substantially longer when given MediGene’s experimental drug EndoTAG-1 on top of standard chemotherapy, according to clinical trial results.

Clinical research Phase II Europe
MORE ON THIS TOPIC
Contemporary art collage of a hand holding scissors. Copy space for ad. Modern design.
Layoffs
Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs
December 19, 2024
 · 
1 min read
 · 
Annalee Armstrong
Roche's signage at its office in France
Parkinson’s disease
Roche’s Prothena-Partnered Parkinson’s Drug Fails Mid-Stage Trial
December 19, 2024
 · 
1 min read
 · 
Annalee Armstrong
Entrance to Vertex's office in Boston, Massachusetts
Pain
Vertex Dips on Mixed Phase II Data for Non-Opioid Pain Therapy
December 19, 2024
 · 
2 min read
 · 
Tristan Manalac
Novo Nordisk advertising flags and logo on facade
Deals
Novo Adds Novel Approach to Cardiometabolic Pipeline With Photys Collab
December 18, 2024
 · 
1 min read
 · 
Kate Goodwin